Results from the Phase 3 Clarity AD study showed that Leqembi reduced cognitive decline by -0.95 on the Clinical Dementia Rating Box Total compared to expected cognitive decline in the untreated group.
Data shows three years of continuous treatment with Leqembi reduces cognitive decline in patients with early-stage Alzheimer’s disease
Leave a comment
